Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.

Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.

The group claims a seven-day vein-to-vein time is unique, and says why this matters.